Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders

Hepatitis C Chronic Clinical Trial

Official title:
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study on Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders to Previous Peg-IFN Alfa-2 Plus Ribavirin Treatment

Status Completed

Clinical Trial Summary

The study is to investigate whether HCV GT1 patients with a history of non-response/relapse to PegIFN + RBV benefit from treatment with triple therapy of DEB025 plus Peg-IFN and ribavirin compared to triple treatment with placebo matching DEB025 plus Peg-IFN and ribavirin

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01183169
Study type	Interventional
Source	Debiopharm International SA
Contact
Status	Completed
Phase	Phase 2
Start date	August 2010
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01544582` - Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)	N/A
Completed	`NCT02161952` - Pirfenidone, an Antifibrotic and Antiinflammatory Drug	Phase 2
Not yet recruiting	`NCT06373198` - Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.